advertisement

---

Wang SY 7

Showing records 1 to 7 | Display all abstracts from Wang SY

96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes
Beykin G
American Journal of Ophthalmology 2021; 234: 223-234

---

96169 The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records Database
Lee EB; Hu W
Ophthalmology 2022; 129: 276-284

---

96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes
Stell L; Halim MS
American Journal of Ophthalmology 2021; 234: 223-234

---

96169 The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records Database
Singh K
Ophthalmology 2022; 129: 276-284

---

96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes
Nuñez M
American Journal of Ophthalmology 2021; 234: 223-234

---

96169 The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records Database
Wang SY
Ophthalmology 2022; 129: 276-284

---

96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes
Popova L; Nguyen BT; Groth SL; Dennis A; Li Z; Atkins M; Khavari T; Wang SY; Chang R; Fisher AC; Sepah YJ; Goldberg JL
American Journal of Ophthalmology 2021; 234: 223-234

---